ClinicalTrials.gg
Not yet recruitingNCT07942246HIPNoSUpdated Nov 17, 2026

Healing and Improving Postnatal Nights Through Sleep (HIPNoS)

An interventional study of Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) and Sleep Hygiene Education (SHE) in Insomnia and Depression, sponsored by Henry Ford Health System. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Henry Ford Health System · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System — 3 open to participants now, 3 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Henry Ford Health System.

Planned enrollment
10th of 15
60 · median 80
Started
2027
the only one that year
No phase
11 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2027, is one of 11 with no phase, and was the 17th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

3 of the 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sleep Initiation and Maintenance Disorders by Henry Ford Health System, or all of them as a file.
02

Study summary

Insomnia and depression are highly prevalent during postpartum, but effective treatment options are severely limited. Perinatal Understanding of Mindful Awareness (PUMAS) combines behavioral sleep strategies and mindfulness-based exercises to improve sleep and mood during pregnancy. Indeed, PUMAS has been shown to effectively treatment comorbid insomnia and depression in pregnancy in controlled and uncontrolled trials. The present randomized controlled trial (RCT) will evaluate the effectiveness of PUMAS in a sample of postpartum women with comorbid insomnia and depression who will be randomized to to telemedicine PUMAS or online sleep hygiene education (SHE; enhanced usual care). Patients will be treated for six weeks followed by assessment after treatment then follow-up assessment 3-months later. The investigators hypothesize that PUMAS patients, relative to SHE patients, will report superior acute treatment effects on insomnia and depression as well as more durable effects at 3-month follow-up.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the trial
  • Participant must be able to engage in treatment (e.g., has internet access to attend telemedicine appointments or access online sleep hygiene materials).
  • Aged 18 years or above.
  • Postpartum 4-12 months at time of screening.
  • Meets diagnostic criteria for insomnia disorder, acute (symptoms lasting ≥1 month).
  • Clinically severe insomnia symptom severity (Insomnia Severity Index score ≥11).
  • depression symptoms (Edinburg Postnatal Depression Scale score ≥10).

Exclusion criteria

Exclusion Criteria:

  • Sleep complaints primarily due to infant sleep problems as ascertained via clinical interview and/or describing the infant's sleep as a 'moderate' or 'serious' problem on the Brief Infant Sleep Questionnaire on the screening survey.
  • Suicidal intent per the Columbus Suicide Severity Rating Scale (Suicidal ideation WITHOUT intent is NOT exclusionary).
  • Current engagement in psychotherapy for insomnia disorder (current use of sleep aids [prescription, over-the-counter, or dietary supplements] is NOT exclusionary).
  • Night or rotating shift work.
  • Unreliable internet access that prevents a patient from being to engage with treatment and/or assessments.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)

    Participants assigned to receive the PUMAS intervention.

    Behavioral: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)

  • Other
    Sleep hygiene education (SHE)

    Participants assigned to receive six weeks of educational materials as an enhanced usual-care control.

    Behavioral: Sleep Hygiene Education (SHE)

Interventions

  • BehavioralPerinatal Understanding of Mindful Awareness for Sleep (PUMAS)

    A six-week psychotherapy protocol combining behavioral sleep strategies with mindfulness exercises with all components tailored to peripartum. PUMAS was initially developed for pregnancy and has been shown to be safe and effective for alleviating insomnia, depression, and cognitive arousal during pregnancy. Early evidence from real-world clinic data has shown that postpartum women with insomnia show the same treatment benefits as prenatal patients, thereby offering early support for effectiveness in pregnancy. PUMAS will be delivered via telemedicine video with a therapist.

  • BehavioralSleep Hygiene Education (SHE)

    Sleep hygiene education (SHE) on maternal sleep and infant sleep. A six-week psychoeducation that will be delivered via six weekly information sheets that will be delivered via email to patients. Perinatal patients report that SHE is the most recommended non-pharmacological treatment suggested for their insomnia. In the real world, SHE is typically delivered in a one-shot information sheet (e.g., after visit summary). However, to match for contact frequency, SHE information will be delivered to patients weekly across six weeks, which also allows for providing greater information on maternal and infant sleep, thereby representing enhanced usual care practice. Although SHE practices improve sleep quality, SHE is not considered an effective standalone treatment for insomnia, therefore making SHE an interventional control comparator.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI)

    The Insomnia Severity Index is a commonly used self-report measure of insomnia symptoms that has been validated in peripartum. ISI scores range from 0 to 28 with higher scores indicating greater insomnia severity.

    Time frame: The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).

Secondary outcomes

  1. Edinburgh Postnatal Depression Scale (EPDS)

    The Edinburgh Postnatal Depression Scale (EDPS) is the most widely use depression measure in pregnancy and postpartum. EPDS scores range from 0 to 30 with higher scores indicating greater depression severity.

    Time frame: The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).

  2. Pre-Sleep Arousal Scale's cognitive factor (PSASC)

    The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in peripartum. PSASC scores range 8 to 40 with higher scores indicating greater nocturnal cognitive arousal.

    Time frame: The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).

07

Study locations

1 site
08

References and documents

Publications

  • Kalmbach DA, Cheng P, Roth T, Swanson LM, Cuamatzi-Castelan A, Roth A, Drake CL. Examining Patient Feedback and the Role of Cognitive Arousal in Treatment Non-response to Digital Cognitive-behavioral Therapy for Insomnia during Pregnancy. Behav Sleep Med. 2022 Mar-Apr;20(2):143-163. doi: 10.1080/15402002.2021.1895793. Epub 2021 Mar 15. PubMed 33719795 ↗
  • Swanson LM, Flynn H, Adams-Mundy JD, Armitage R, Arnedt JT. An open pilot of cognitive-behavioral therapy for insomnia in women with postpartum depression. Behav Sleep Med. 2013;11(4):297-307. doi: 10.1080/15402002.2012.683902. Epub 2012 Dec 6. PubMed 23216373 ↗
  • Kalmbach DA, Cheng P, Drake CL. A pathogenic cycle between insomnia and cognitive arousal fuels perinatal depression: exploring the roles of nocturnal cognitive arousal and perinatal-focused rumination. Sleep. 2021 Jun 11;44(6):zsab028. doi: 10.1093/sleep/zsab028. PubMed 33830248 ↗
  • Kalmbach DA, Cheng P, Ong JC, Ciesla JA, Kingsberg SA, Sangha R, Swanson LM, O'Brien LM, Roth T, Drake CL. Depression and suicidal ideation in pregnancy: exploring relationships with insomnia, short sleep, and nocturnal rumination. Sleep Med. 2020 Jan;65:62-73. doi: 10.1016/j.sleep.2019.07.010. Epub 2019 Jul 22. PubMed 31710876 ↗
  • Kalmbach DA, Cheng P, Sangha R, O'Brien LM, Swanson LM, Palagini L, Bazan LF, Roth T, Drake CL. Insomnia, Short Sleep, And Snoring In Mid-To-Late Pregnancy: Disparities Related To Poverty, Race, And Obesity. Nat Sci Sleep. 2019 Nov 4;11:301-315. doi: 10.2147/NSS.S226291. eCollection 2019. PubMed 31807103 ↗
  • Kalmbach DA, Ong JC, Cheng P, Reffi AN, Swanson LM, Hirata M, Seymour GM, Castelan-Cuamatzi AS, Jennings MB, Pitts DS, Roth A, Roth T, Drake CL. A randomized controlled trial of telemedicine CBTI and PUMAS for prenatal insomnia: Reducing nocturnal cognitive arousal is a treatment mechanism for alleviating insomnia and depression during pregnancy. Sleep Med. 2025 Sep;133:106570. doi: 10.1016/j.sleep.2025.106570. Epub 2025 May 12. PubMed 40413907 ↗
  • Kalmbach DA, Cheng P, Reffi AN, Ong JC, Swanson LM, Fresco DM, Walch O, Seymour GM, Fellman-Couture C, Bayoneto AD, Roth T, Drake CL. Perinatal Understanding of Mindful Awareness for Sleep (PUMAS): A single-arm proof-of-concept clinical trial of a mindfulness-based intervention for DSM-5 insomnia disorder during pregnancy. Sleep Med. 2023 Aug;108:79-89. doi: 10.1016/j.sleep.2023.05.026. Epub 2023 Jun 10. PubMed 37343335 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2029, 25 months later.

Of 1,212 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 25 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Nov 17, 2026
StartEst.
Jan 3, 2027
Primary completionEst.
Mar 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942246
Responsible party
David Kalmbach (Principal Investigator, Henry Ford Health System) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 3, 2027 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Heba Research Operations Manager
Contact
hafaneh1@HFHS.ORG
(248) 344-7363
David A. Kalmbach, PhD
principal investigator · Henry Ford Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion